Biotech | September 03, 2021
Omeza Collegen Matrix gets U.S. FDA approval
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
PPH is associated with almost 20 per cent of maternal mortality in India
The centre established by Nucleome Informatics will take up the sequencing of 5,000 Covid genomes and 500 human genomes in the coming months
To prevent the state from facing a shortage of medical oxygen and to bolster the existing infrastructure, the SRAM & MRAM group is actively helping the state government to set up oxygen plants in multiple cities
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Subscribe To Our Newsletter & Stay Updated
